{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:57:11Z","timestamp":1789610231958,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015756","name":"Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.eimc.2020.01.017","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T08:00:53Z","timestamp":1583222453000},"page":"474-478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Characterization of AmpC \u03b2-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane\/tazobactam during therapy"],"prefix":"10.1016","volume":"38","author":[{"given":"Marta","family":"Fern\u00e1ndez-Esgueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"L\u00f3pez-Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo A.","family":"Fraile-Ribot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Cabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Huarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rezusta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.eimc.2020.01.017_bib0120","doi-asserted-by":"crossref","first-page":"i29","DOI":"10.1093\/jac\/dkp255","article-title":"Has the era of untreatable infections arrived?","volume":"64","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0125","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.eimc.2020.01.017_bib0130","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2146\/ajhp150049","article-title":"Ceftolozane\u2013tazobactam: a new-generation cephalosporin","volume":"72","author":"Cluck","year":"2015","journal-title":"Am J Heal Pharm"},{"key":"10.1016\/j.eimc.2020.01.017_bib0135","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1128\/AAC.01104-09","article-title":"Activity of a new cephalosporin, CXA-101 (FR264205), against \u03b2-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients","volume":"54","author":"Moya","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0140","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane\u2013tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.017_bib0150","first-page":"1","article-title":"In vivo resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways","volume":"2018","author":"Skoglund","year":"2018","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.017_bib0155","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.eimc.2020.01.017_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01117-17","article-title":"In vivo emergence of resistance to novel cephalosporin\u2013\u03b2-Lactamase inhibitor combinations through the duplication of amino acid D149 from OXA-2 \u03b2-Lactamase (OXA-539) in sequence type 235 Pseudomonas aeruginosa","volume":"61","author":"Fraile-Ribot","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0165","first-page":"33","article-title":"Pulsed-field gel electrophoresis","volume":"vol. 15","author":"Kaufmann","year":"1998"},{"key":"10.1016\/j.eimc.2020.01.017_bib0170","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1128\/JCM.42.12.5644-5649.2004","article-title":"Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa","volume":"42","author":"Curran","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.eimc.2020.01.017_bib0175","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane\u2013tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0180","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.017_bib0185","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.eimc.2020.01.017_bib0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Escol\u00e0-Verg\u00e9","year":"2018","journal-title":"Infection"},{"key":"10.1016\/j.eimc.2020.01.017_bib0195","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1128\/AAC.01388-12","article-title":"Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones","volume":"56","author":"Cabot","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0200","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01183-17","article-title":"Emergence of ceftolozane\u2013tazobactam-resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation","volume":"61","author":"MacVane","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0205","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01637-19","article-title":"A 2.5-year within-patient evolution of Pseudomonas aeruginosa isolates with in vivo acquisition of ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam resistance upon treatment","volume":"63","author":"Boulant","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0210","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02085-18","article-title":"Deciphering the evolution of cephalosporin resistance to ceftolozane tazobactam in Pseudomonas aeruginosa","volume":"9","author":"Barnes","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.eimc.2020.01.017_bib0215","article-title":"Acquisition of extended-spectrum \u03b2-lactamase GES-6 leading to resistance to ceftolozane\u2013tazobactam combination in Pseudomonas aeruginosa","volume":"63","author":"Poirel","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0220","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz273","article-title":"Extensively drug-resistant Pseudomonas aeruginosa ST309 harboring tandem Guiana extended spectrum \u03b2-Lactamase enzymes: a newly emerging threat in the United States","volume":"6","author":"Khan","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.eimc.2020.01.017_bib0225","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01110-19","article-title":"Challenging antimicrobial susceptibility and evolution of resistance (OXA-681) during treatment of a Pseudomonas aeruginosa ST175 clone long-term nosocomial infection","volume":"63","author":"Arca-Su\u00e1rez","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.eimc.2020.01.017_bib0230","article-title":"A standard numbering scheme for class C \u03b2-lactamases","author":"Mack","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20300240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X20300240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:06:01Z","timestamp":1759323961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X20300240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0213005X20300240"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2020.01.017","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of AmpC \u03b2-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane\/tazobactam during therapy","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2020.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}